重组人干扰素α-1b雾化吸入治疗毛细支气管炎的临床疗效观察  

Clinical effect of aerosol inhalation of recombinant human interferon α-1b in the treatment of bronchiolitis

作　　者：陈静华[1] Chen Jinghua(The People's Hospital of Renhuai City,Guizhou Province,Guizhou Renhuai 564500)

机构地区：[1]贵州省仁怀市人民医院

出　　处：《中国社区医师》2020年第5期14-15,共2页Chinese Community Doctors

摘　　要：目的:探究重组人干扰素α-1b雾化吸入治疗小儿毛细支气管炎的临床疗效。方法:2018年9月-2019年5月收治毛细支气管炎患儿88例,随机分为两组,各44例。对照组采用常规治疗方法;观察组在常规治疗基础上进行重组人干扰素α-1b雾化吸入治疗。比较两组治疗效果。结果:观察组缓解率显著高于对照组,住院时间、肺部哮鸣音、临床憋喘及咳嗽症状消失时间均优于对照组,差异有统计学意义(P<0.05)。结论:重组人干扰素α-1b雾化吸入治疗小儿毛细支气管炎疗效显著,可使患儿病情及肺功能得到改善,加快症状消失时间,减少住院时间。Objective:To explore the clinical effect of aerosol inhalation of recombinant human interferonα-1b in the treatment of bronchiolitis.Methods:From September 2018 to May 2019,88 children with bronchiolitis were selected and randomly divided into two groups of 44 cases in each.The control group was treated with conventional treatment,the observation group was treated with aerosol inhalation of recombinant human interferonα-1b on the basis of conventional treatment.We compared the efficacy of the two groups.Results:In the observation group,the remission rate was significantly higher than that in the control group,and the hospitalization time,lung wheezing sound,clinical suffocation and cough symptom disappearance time were all better than those in the control group,the difference was statistically significant(P<0.05).Conclusion:The clinical effect of aerosol inhalation of recombinant human interferonα-1b in the treatment of bronchiolitis is significant,it can improve the patient's condition and lung function,speed up the disappearance time of symptoms and reduce the hospitalization time.

关 键 词：重组人干扰素Α-1B 雾化吸入 小儿毛细支气管炎 

分 类 号：R725.6[医药卫生—儿科]